Literature DB >> 24618065

Lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts.

H M Crane, S R Heckbert, D R Drozd, M J Budoff, J A C Delaney, C Rodriguez, P Paramsothy, W B Lober, G Burkholder, J H Willig, M J Mugavero, W C Mathews, P K Crane, R D Moore, S Napravnik, J J Eron, P Hunt, E Geng, P Hsue, G S Barnes, J McReynolds, I Peter, C Grunfeld, M S Saag, M M Kitahata.   

Abstract

We developed, implemented, and evaluated a myocardial infarction (MI) adjudication protocol for cohort research of human immunodeficiency virus. Potential events were identified through the centralized Centers for AIDS Research Network of Integrated Clinical Systems data repository using MI diagnoses and/or cardiac enzyme laboratory results (1995-2012). Sites assembled de-identified packets, including physician notes and results from electrocardiograms, procedures, and laboratory tests. Information pertaining to the specific antiretroviral medications used was redacted for blinded review. Two experts reviewed each packet, and a third review was conducted if discrepancies occurred. Reviewers categorized probable/definite MIs as primary or secondary and identified secondary causes of MIs. The positive predictive value and sensitivity for each identification/ascertainment method were calculated. Of the 1,119 potential events that were adjudicated, 294 (26%) were definite/probable MIs. Almost as many secondary (48%) as primary (52%) MIs occurred, often as the result of sepsis or cocaine use. Of the patients with adjudicated definite/probable MIs, 78% had elevated troponin concentrations (positive predictive value = 57%, 95% confidence interval: 52, 62); however, only 44% had clinical diagnoses of MI (positive predictive value = 45%, 95% confidence interval: 39, 51). We found that central adjudication is crucial and that clinical diagnoses alone are insufficient for ascertainment of MI. Over half of the events ultimately determined to be MIs were not identified by clinical diagnoses. Adjudication protocols used in traditional cardiovascular disease cohorts facilitate cross-cohort comparisons but do not address issues such as identifying secondary MIs that may be common in persons with human immunodeficiency virus.

Entities:  

Keywords:  HIV; myocardial infarction; validation

Mesh:

Year:  2014        PMID: 24618065      PMCID: PMC3966717          DOI: 10.1093/aje/kwu010

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  69 in total

1.  Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.

Authors:  E L Murphy; A C Collier; L A Kalish; S F Assmann; M F Para; T P Flanigan; P N Kumar; L Mintz; F R Wallach; G J Nemo
Journal:  Ann Intern Med       Date:  2001-07-03       Impact factor: 25.391

2.  The new and old definitions of acute myocardial infarction: a data-based comparison.

Authors:  John Tobias Nagurney; Calvin Huang; Orlando Heredia; Swati Sane; Sarah C Lewis; Yuchiao Chang; Ik-Kyung Jang
Journal:  Am J Emerg Med       Date:  2008-06       Impact factor: 2.469

3.  Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.

Authors: 
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

4.  The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C.

Authors:  Matthew S Freiberg; Chung-Chou H Chang; Melissa Skanderson; Kathleen McGinnis; Lewis H Kuller; Kevin L Kraemer; David Rimland; Matthew B Goetz; Adeel A Butt; Maria C Rodriguez Barradas; Cynthia Gibert; David Leaf; Sheldon T Brown; Jeffrey Samet; Lewis Kazis; Kendall Bryant; Amy C Justice
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-06-28

5.  False-positive coding for acute myocardial infarction on hospital discharge records: chart audit results from a tertiary centre.

Authors:  C van Walraven; B Wang; A M Ugnat; C D Naylor
Journal:  Can J Cardiol       Date:  1990-11       Impact factor: 5.223

6.  Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.

Authors:  Samuel A Bozzette; Christopher F Ake; Henry K Tam; Sophia W Chang; Thomas A Louis
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

7.  Coronary heart disease in HIV-infected individuals.

Authors:  Judith S Currier; Anne Taylor; Felicity Boyd; Christopher M Dezii; Hugh Kawabata; Beth Burtcel; Jen-Fue Maa; Sally Hodder
Journal:  J Acquir Immune Defic Syndr       Date:  2003-08-01       Impact factor: 3.731

8.  Coding of acute myocardial infarction. Clinical and policy implications.

Authors:  L I Iezzoni; S Burnside; L Sickles; M A Moskowitz; E Sawitz; P A Levine
Journal:  Ann Intern Med       Date:  1988-11-01       Impact factor: 25.391

9.  The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.

Authors: 
Journal:  Can J Cardiol       Date:  1996-02       Impact factor: 5.223

10.  Systematic adjudication of myocardial infarction end-points in an international clinical trial.

Authors:  Kenneth W Mahaffey; Robert A Harrington; Martijn Akkerhuis; Neal S Kleiman; Lisa G Berdan; Brian S Crenshaw; Barbara E Tardiff; Christopher B Granger; Ingrid DeJong; Manju Bhapkar; Petr Widimsky; Ramón Corbalon; Kerry L Lee; Jaap W Deckers; Maarten L Simoons; Eric J Topol; Robert M Califf
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001-07-17
View more
  26 in total

1.  Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States.

Authors:  Heidi M Crane; Robin M Nance; Susan R Heckbert; Corey Ritchings; Lisa Rosenblatt; Matthew Budoff; Brian R Wood; David L Tirschwell; H Nina Kim; William C Mathews; Elvin Geng; Richard D Moore; Peter W Hunt; Joseph J Eron; Greer A Burkholder; Daniel R Drozd; Felicia C Chow; Kyra J Becker; Joseph R Zunt; Emily L Ho; Rizwan Kalani; Andrew Huffer; Bridget M Whitney; Michael S Saag; Mari M Kitahata; Joseph A C Delaney
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-15       Impact factor: 3.731

Review 2.  Recent Insights Into Cardiovascular Disease (CVD) Risk Among HIV-Infected Adults.

Authors:  Robert C Kaplan; David B Hanna; Jorge R Kizer
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

3.  The authors reply.

Authors:  H M Crane; S R Heckbert; D R Drozd; M J Budoff; J A C Delaney; C Rodriguez; P Paramsothy; W B Lober; G Burkholder; J H Willig; M J Mugavero; W C Mathews; P K Crane; R D Moore; S Napravnik; J J Eron; P Hunt; E Geng; P Hsue; G S Barnes; J McReynolds; I Peter; C Grunfeld; M S Saag; M M Kitahata
Journal:  Am J Epidemiol       Date:  2014-07-02       Impact factor: 4.897

4.  Assessing and Refining Myocardial Infarction Risk Estimation Among Patients With Human Immunodeficiency Virus: A Study by the Centers for AIDS Research Network of Integrated Clinical Systems.

Authors:  Matthew J Feinstein; Robin M Nance; Daniel R Drozd; Hongyan Ning; Joseph A Delaney; Susan R Heckbert; Matthew J Budoff; William C Mathews; Mari M Kitahata; Michael S Saag; Joseph J Eron; Richard D Moore; Chad J Achenbach; Donald M Lloyd-Jones; Heidi M Crane
Journal:  JAMA Cardiol       Date:  2017-02-01       Impact factor: 14.676

5.  Computerized Adjudication of Coronary Heart Disease Events Using the Electronic Medical Record in HIV Clinical Research: Possibilities and Challenges Ahead.

Authors:  Michelle Floris-Moore; Andrew Edmonds; Sonia Napravnik; Adaora A Adimora
Journal:  AIDS Res Hum Retroviruses       Date:  2019-09-10       Impact factor: 2.205

6.  Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population.

Authors:  Daniel R Drozd; Mari M Kitahata; Keri N Althoff; Jinbing Zhang; Stephen J Gange; Sonia Napravnik; Greer A Burkholder; William C Mathews; Michael J Silverberg; Timothy R Sterling; Susan R Heckbert; Matthew J Budoff; Stephen Van Rompaey; Joseph A C Delaney; Cherise Wong; Weiqun Tong; Frank J Palella; Richard A Elion; Jeffrey N Martin; John T Brooks; Lisa P Jacobson; Joseph J Eron; Amy C Justice; Matthew S Freiberg; Daniel B Klein; Wendy S Post; Michael S Saag; Richard D Moore; Heidi M Crane
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-15       Impact factor: 3.731

7.  Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors.

Authors:  Robin M Nance; Heidi M Crane; Corey Ritchings; Lisa Rosenblatt; Matthew Budoff; Susan R Heckbert; Daniel R Drozd; William C Mathews; Elvin Geng; Peter W Hunt; Matthew J Feinstein; Richard D Moore; Priscilla Hsue; Joseph J Eron; Greer A Burkholder; Benigno Rodriguez; Michael J Mugavero; Michael S Saag; Mari M Kitahata; Joseph A C Delaney
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-21       Impact factor: 2.205

8.  Death after diagnosis of noncommunicable disease comorbid conditions, stratified by injection drug use.

Authors:  Catherine R Lesko; Bryan Lau; Geetanjali Chander; Richard D Moore
Journal:  AIDS       Date:  2019-02-01       Impact factor: 4.177

9.  Cumulative Human Immunodeficiency Viremia, Antiretroviral Therapy, and Incident Myocardial Infarction.

Authors:  Joseph A Delaney; Robin M Nance; Bridget M Whitney; Heidi M Crane; Jessica Williams-Nguyen; Mathew J Feinstein; Robert C Kaplan; David B Hanna; Matthew J Budoff; Daniel R Drozd; Greer Burkholder; Michael J Mugavero; William C Mathews; Richard D Moore; Joseph J Eron; Peter W Hunt; Elvin Geng; Michael S Saag; Mari M Kitahata; Susan R Heckbert
Journal:  Epidemiology       Date:  2019-01       Impact factor: 4.822

10.  Association of injection drug use with incidence of HIV-associated non-AIDS-related morbidity by age, 1995-2014.

Authors:  Catherine R Lesko; Richard D Moore; Weiqun Tong; Bryan Lau
Journal:  AIDS       Date:  2016-06-01       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.